Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: Does it really work?

Paolo Cravedi, Varusca Brusegan, Piero Ruggenenti, Ruth Campbell, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review

Abstract

We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and >3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to asystolic/diastolic blood pressure

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalPharmaceuticals
Volume3
Issue number1
DOIs
Publication statusPublished - 2010

Keywords

  • Hyperkalemia
  • Idiopathic membranous nephropathy
  • Proteinuria
  • Spironolactone

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: Does it really work?'. Together they form a unique fingerprint.

Cite this